drugset / Trial / NCT05645601
CAR-NK Targeted CD19 for r/r B-cell Malignancies
Phase 1
Unknown
12 enrolled
Affiliated Hospital to Academy of Military Medical Sciences
Beijing JD Biotech Co. LTD. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of JD010 in adult patients with relapsed or refractory B cell hematologic malignancies. JD010 injection is a CD19-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) derived from a healthy donor
Timeline
- Start
- 2022-12-01
- Primary completion
- 2024-05-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-CAR-NK | Cell therapy | 5e+06 cells/kg | — |
| Subject | CD19-CAR-NK | Cell therapy | 2e+07 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |